Navigation Links
Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush
Date:3/26/2009

PARIS, March 26 /PRNewswire-FirstCall/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today the appointment of Dr. Karen Bush to the Company's Scientific Advisory Board (SAB). Novexel's SAB is chaired by Dr. David Shlaes who sits on the Company's board. Dr. Bush, who is currently Adjunct Professor at the Department of Biology at Indiana University, brings extensive experience and knowledge of the anti-infectives field to Novexel's SAB.

Dr. Bush's distinguished scientific career in anti-infective research and development spans over three decades and she is a recognised authority in the study of resistance mediated by beta-lactamases. During her career, Dr. Bush has held the position of Distinguished Research Fellow at Johnson & Johnson, Director of Microbial Biochemistry at the Astra Research Center, Boston, MA; Senior Research Fellow, Infectious Disease at Wyeth and Principal Investigator at the Department of Microbiology at Bristol Myers Squibb. Over this period, Dr. Bush was a member of the scientific teams that developed a portfolio of leading hospital antibiotics including levofloxacin (Levaquin), doripenem (Doribax). aztreonam (Azactam) and piperacillin-tazobactam (Zozyn).

Dr. Bush received her Ph.D. from the Indiana University Chemistry Department in 1970 and has since authored over 160 peer-reviewed publications and 17 book chapters. Dr. Bush has also served on the Editorial Boards of several internationally renowned journals including Antimicrobial Agents and Chemotherapy and the European Journal of Clinical Microbiology and Infectious Diseases. Dr. Bush is a member of the Program Committee for one of the anti-infectives industry's most important conferences, the Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC. Moreover, Dr. Bush was elected a Fellow of the American Academy of Microbiology in 2000, in recognition of her record of scientific achievement and original contributions to microbiology

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $17bn in 2008.[1]

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by our partner, Forest Laboratories, solely for North American markets.

Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel has a team of 50 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA.

    [1] Source: IMS Health, MIDAS, 2006-2008

    For further information please contact:

    Novexel
    Gordon Waldron, CFO
    gordon.waldron@novexel.com

    Citigate Dewe Rogerson
    Amber Bielecka/David Dible/Nina Enegren
    Tel.: +44-(0)207-638-95-71
    amber.bielecka@citigatedr.co.uk



'/>"/>
SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
2. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs
3. Trillium Strengthens its Board of Directors
4. Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
5. Ikaria Strengthens Executive Leadership Team
6. Algenol Biofuels Further Strengthens Team With Key Appointments
7. InNexus Biotechnology Strengthens Patent Team With New Leadership
8. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
9. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
10. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
11. Milestone Biosciences, LLC Further Strengthens Executive Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., ... groundbreaking therapies to treat severe neurological disorders, today ... treated with AGT-181, the company,s investigational therapy for ... known as mucopolysaccharidosis type I, or MPS I). ... proof-of-concept (POC) study, presented today at the 13 ...
(Date:2/16/2017)... , Feb. 16, 2017   Biostage, Inc. ... "Company"), a biotechnology company developing bioengineered organ implants to ... bronchus and trachea, announced today the closing on February ... 20,000,000 shares of common stock and warrants to purchase ... of $8.0 million. The offering was priced at $0.40 ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 Report Highlights The global ... $8.3 billion in 2016 at a compound annual growth ... Report Includes - An overview of the global market ... data from 2015 and 2016, and projections of compound ... the market on the basis of product type, source, ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a ... a new white paper " What You Should Know ... problem of ensuring user authenticity is a growing concern. ... authentication of users. However, traditional authentication schemes such as ... Biometric authentication offers an elegant solution to ...
Breaking Biology News(10 mins):